查看更多>>摘要：Linked Article:?Kempf et?al. Br J Dermatol 2022; 186:887–897. CD8+ cutaneous lymphomas are skin cancers that arise from types of cells that are important in immune defences called CD8+ T‐lymphocytes. CD8+ cutaneous lymphomas are rare cancers. There are several different types – they share some histological features (features that can be seen under the microscope) but some types are more serious than others. Knowing more about them will help with diagnosis and treatment. This study, with authors and patients from around the world, set out in improve our understanding about the clinical and histological features of these cancers, their outcome and their differences. Knowing more about their differences will help make sure patients receive the best treatment for the specific type of CD8+ cutaneous lymphoma they have. Data about 46 patients with 55 skin biopsies (where a small section of tissue is removed for testing) were analysed by the international European Organisation for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Group. They found that these cancers could be divided into three distinct groups. The first group is: cutaneous acral CD8+ T‐cell lymphoma. There were 31 patients with this type. The outcome for this type is generally good. The second group is: primary cutaneous CD8+ peripheral T‐cell lymphoma, unspecified/not otherwise specified. There were 11 patients with this type. The third group is: cutaneous CD8+ tumours associated with congenital or acquired immunodeficiency syndromes. There were four patients with this type. The findings of this study will help doctors to diagnose the specific type of CD8+ cutaneous lymphoma patients have so that they can receive the most appropriate treatment.
NSTL
Wiley